Should MRI be the primary endpoint of phase III trials in MS? No

被引：0

作者：

Weinshenker, B. G. ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

107

引用

页码：28 / 28

页数：1

共 50 条

[1] MRI as primary endpoint of clinical trials should MRI be the PEP of phase III trials in MS? YES
Sormani, M. P.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
[2] Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?
Rossman, Ian T.
Cohen, Jeffrey A.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (05) : 489 - 491
[3] MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No
Ebers, George C.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 282 - 283
[4] MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes
Sormani, Maria Pia
De Stefano, Nicola
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 280 - 281
[5] MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary
Hutchinson, Michael
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 284 - 285
[6] Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials
Djulbegovic, Benjamin
Kumar, Ambuj
Miladinovic, Branko
Mhaskar, Asmita
Reljic, Tea
Galeb, Sanja
Mhaskar, Rahul
Iztok, Hozo
Tu, Dongsheng
Stanton, Heather
Booth, Christopher M.
Meyer, Ralph M.
BLOOD, 2011, 118 (21) : 237 - 237
[7] Thalamic Atrophy as Primary Endpoint for Phase 2 Trials in MS: Sample Size Calculations
Azevedo, Christina
Pelletier, Daniel
NEUROLOGY, 2016, 86
[8] Associations between prognosis and primary endpoint selection in phase III oncology trials in the United States
Uemura, Nariaki
Ono, Shunsuke
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] HOW SHOULD THE PRIMARY ENDPOINT BE ANALYSED IN RHEUMATOID ARTHRITIS TRIALS WHICH MANDATE RESCUE PRIOR TO THE CLINICAL ENDPOINT? ANALYSIS OF THREE PHASE 3 TRIALS OF TOFACITINIB
Fleischmann, R.
Gruben, D.
Krishnaswami, S.
Zwillich, S. H.
Benda, B.
Mebus, C. A.
Bradley, J.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 207 - 207
[10] Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials
Markman, Maurie
GYNECOLOGIC ONCOLOGY, 2007, 106 (02) : 279 - 281

← 1 2 3 4 5 →